Provide a summary of the listed HIV‑1 reverse transcriptase, integrase, and protease mutations and assess the appropriateness of Cabenuva (cabotegravir + rilpivirine) for this patient, presented as a chart note.

HIV-1 Resistance Mutation Summary and Cabenuva Appropriateness Assessment

Resistance Profile Analysis

Cabenuva (cabotegravir/rilpivirine long-acting) is NOT appropriate for this patient due to documented resistance mutations to both components of the regimen.

Reverse Transcriptase (RT) Mutations

The patient harbors multiple RT mutations including:

• K43E, S68G, K122P, C162S, I178L, T200A, R211K, A272P, R277K, T286A, V293I: These represent a complex resistance pattern
• Mixed populations: T39T/K, I63I/M, D177D/N, L264L/F, V292V/I indicate ongoing viral evolution

While none of these are classic major NNRTI resistance mutations (e.g., K103N, Y181C, G190A), the presence of multiple accessory mutations raises concern for reduced rilpivirine susceptibility, particularly in combination.

Integrase (IN) Mutations

The integrase profile shows:

• No major INSTI resistance mutations detected (Q148H/K/R, N155H, G118R, R263K are absent)
• Y227F: This is a polymorphic accessory mutation that may contribute to reduced cabotegravir susceptibility when combined with major mutations 1
• Other mutations (E11D, R20K, V72I, V113I, T124A, F181L, V201I, I220L, V234L) are primarily polymorphic variants

Protease (PR) Mutations

• I64V: Minor protease inhibitor resistance mutation
• Other mutations (E35D, N37E, D60E) are polymorphic variants

Clinical Recommendation

This patient should NOT receive Cabenuva based on current IAS-USA 2024 guidelines, which explicitly state that long-acting cabotegravir plus rilpivirine is not recommended in individuals with documented or suspected resistance to either agent (evidence rating: AIIa) 2.

Key Contraindications:

1. Complex RT mutation pattern: While major NNRTI mutations are absent, the constellation of multiple RT mutations creates uncertainty about rilpivirine susceptibility
2. Guideline violation: The 2024 IAS-USA panel clearly contraindicates CAB/RPV LA when resistance to either component is documented or suspected 2
3. Risk of virologic failure: Studies demonstrate that archived resistance mutations, even when present as minority variants, can lead to treatment failure 1, 3

Alternative Treatment Approach

Recommended regimen: Dolutegravir or bictegravir-based therapy with tenofovir/emtricitabine (or lamivudine)

Rationale:

• High barrier to resistance: Dolutegravir and bictegravir maintain efficacy even with NRTI resistance 2
• No major INSTI mutations present: The absence of Q148H/K/R, N155H, or G118R makes these agents fully active 1, 4
• Guideline-supported: IAS-USA 2024 recommends dolutegravir or bictegravir plus 2 NRTIs for virologic failure scenarios 2
• Superior outcomes: Bictegravir shows the lowest rates of virologic failure and resistance development among INSTIs 4

Monitoring Requirements:

• Close virologic monitoring in first year after switch, especially given complex resistance history 2
• HIV-1 RNA at weeks 4,8,12, then every 3-4 months
• Resistance testing if any detectable viremia >200 copies/mL

Critical Pitfalls to Avoid

1. Do not use proviral DNA resistance testing alone to determine CAB/RPV LA eligibility—many archived mutations are in defective proviruses and may not reflect true resistance risk 5, 6
2. Do not ignore complex mutation patterns: Even without classic major mutations, multiple accessory mutations can compromise efficacy
3. Do not use CAB/RPV LA as salvage therapy: This regimen is designed for virologically suppressed patients without resistance, not for treatment-experienced patients with complex histories 2, 7

Documentation Note:

"Patient presents with complex HIV-1 resistance profile including multiple RT mutations and polymorphic IN variants. Per IAS-USA 2024 guidelines, Cabenuva is contraindicated due to documented resistance mutations. Recommend dolutegravir or bictegravir-based regimen with close virologic monitoring." 2